Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

Authors

Dana M. Roque, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Eric R. Siegel, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Natalia Buza, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Stefania Bellone, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Dan-Arin Silasi, Division of Gynecologic Oncology, Mercy Clinic, St. Louis, MO, USA.
Gloria S. Huang, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Vaagn Andikyan, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Mitchell Clark, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Masoud Azodi, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Peter E. Schwartz, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Gautam G. Rao, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Jocelyn C. Reader, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Pei Hui, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Joan R. Tymon-Rosario, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Justin Harold, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Dennis Mauricio, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Burak Zeybek, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Gulden Menderes, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Gary Altwerger, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Elena Ratner, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Alessandro D. Santin, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA. alessandro.santin@yale.edu.

Document Type

Article

Publication Title

British journal of cancer

First Page

1073

DOI

10.1038/s41416-024-02628-4

Publication Date

4-1-2024

Recommended Citation

Roque, Dana M.; Siegel, Eric R.; Buza, Natalia; Bellone, Stefania; Silasi, Dan-Arin; Huang, Gloria S.; Andikyan, Vaagn; Clark, Mitchell; Azodi, Masoud; Schwartz, Peter E.; Rao, Gautam G.; Reader, Jocelyn C.; Hui, Pei; Tymon-Rosario, Joan R.; Harold, Justin; Mauricio, Dennis; Zeybek, Burak; Menderes, Gulden; Altwerger, Gary; Ratner, Elena; and Santin, Alessandro D., "Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer" (2024). Randomized Controlled Trials. 51.
https://scholar.bridgeporthospital.org/randomized_trial/51

Identifier

38438590 (pubmed); PMC10951353 (pmc); 10.1038/s41416-024-02628-4 (doi); 10.1038/s41416-024-02628-4 (pii)